Bayani-671, KEYTRUDA, Merck, Bayanin NSCLC, Pembrolizumab
Neoadjuvant/adjuvant pembrolizumab an amince da shi daga FDA don sake sake fasalin cutar kansar huhu mara ƙarami.
Nov 2023: Pembrolizumab (Keytruda, Merck) ya sami izini daga Hukumar Abinci da Magunguna (FDA) a matsayin maganin neoadjuvant a hade tare da chemotherapy mai ɗauke da platinum kuma azaman maganin adjuvant na bayan tiyata f..
Array BioPharma Inc. girma, binimetinib, Braftova, encorafenib, Mektovi, Pfizer
Encorafenib tare da binimetinib an amince da ita ta FDA don maganin ciwon huhu mara ƙananan ƙwayar cuta tare da maye gurbin BRAF V600E.
Hukumar Abinci da Magunguna (FDA) ta amince da Encorafenib (Braftovi, Array BioPharma Inc., reshen mallakar Pfizer gaba ɗaya) da binimetinib (Mektovi, Array BioPharma Inc.) a cikin Nuwamba 2023 a matsayin magunguna waɗanda za a iya amfani da su don…
Gwajin Arrow, Gaskiya, Bayanin NSCLC, pralsetinib
FDA ta amince da Pralsetinib don ciwon daji na huhu mara ƙarami tare da haɗakar halittar RET
Agusta 2023: Pralsetinib (Gavreto, Genentech, Inc.) An ba da izini akai-akai ta Cibiyar Abinci da Magunguna don manya marasa lafiya tare da ciwon daji na huhu na huhu (NSCLC), kamar yadda FDA ta ƙaddara.
FDA, Abinci da Drug Administration, KEYTRUDA, Merck, Pembrolizumab, chemotherapy na tushen platinum
Pembrolizumab an amince da shi ta FDA a matsayin jiyya don ciwon huhu mara ƙarami
Feb 2023: Don mataki IB (T2a 4 cm), mataki na II, ko mataki IIIA ciwon huhu mara karami, Hukumar Abinci da Magunguna (FDA) ta amince da pembrolizumab (Keytruda, Merck) a matsayin maganin adjuvant bayan resection da platinum na tushen chemoth. ..
AstraZeneca Pharmaceuticals, durkushewa, Imjudo, Bayanin NSCLC, POSEIDON, tremelimumab
Tremelimumab an amince da ita ta FDA a hade tare da durvalumab da maganin cutar sankara na platinum don ciwon huhu mara ƙananan ƙwayar cuta.
Nuwamba 2022: Haɗin tremelimumab (Imjudo, AstraZeneca Pharmaceuticals), durvalumab (Imfinzi, AstraZeneca Pharmaceuticals), da kuma tushen cutar sankara na platinum an amince da su ta Hukumar Abinci da Magunguna don manya pa..
Libya, NCT03409614, Bayanin NSCLC, chemotherap na tushen platinum, Magungunan Regeneron
Cemiplimab-rwlc ta amince da FDA a hade tare da maganin cutar sankara na platinum don ciwon huhu mara karami.
Nuwamba 2022: Haɗuwa da cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) da kuma tushen ƙwayar cuta ta platinum don manya marasa lafiya waɗanda ke da ci-gaban ciwon huhu mara ƙananan ƙwayoyin cuta (NSCLC) ba tare da EGFR, ALK, ko ROS1 rashin daidaituwa ba.
am-trastuzumab deruxtecan-nxki, Daichi Sankyo, Enhertu
An ba da izini da sauri ta FDA ga fam-trastuzumab deruxtecan-nxki don HER2-mutant wanda ba ƙananan ƙwayar huhu ba.
Agusta 2022: Ga manya marasa lafiya masu ciwon huhu marasa ƙananan ƙwayoyin cuta (NSCLC) waɗanda ciwace-ciwacen su ke da maye gurbi wanda ya haifar da mizanin mesenchymal-epithelial (MET) exon 14 skipping, kamar yadda gwajin da FDA ta amince da shi, Abinci.
Capmatinib, NCT02414139, Novartis Pharmaceuticals Corp. girma, Bayanin NSCLC, Tabrecta
Capmatinib an yarda da shi don ciwon huhu na huhu wanda ba ƙananan ƙananan ƙwayoyin cuta ba
Agusta 2022: Ga manya marasa lafiya masu ciwon huhu marasa ƙananan ƙwayoyin cuta (NSCLC) waɗanda ciwace-ciwacen su ke da maye gurbi wanda ya haifar da mizanin mesenchymal-epithelial (MET) exon 14 skipping, kamar yadda gwajin da FDA ta amince da shi, Abinci.
BMS, Farashin-816, nivolumab, Bayanin NSCLC, Abin al'ajabi
Neoadjuvant nivolumab da platinum-double chemotherapy an yarda da su don ciwon huhu mara ƙarami a matakin farko.
Maris 2022: A cikin saitin neoadjuvant, FDA ta amince da nivolumab (Opdivo, Kamfanin Bristol-Myers Squibb) a hade tare da maganin chemotherapy na platinum-biyu don manya masu fama da cutar kansar huhun huhun da ba na ƙananan ƙwayoyin cuta (NSCLC) ba.
Atezolizumab, Gaskiya, Bayanin NSCLC, Tecentriq, Tsarin Kiwon Lafiya na Ventana, Farashin PD-L1
Atezolizumab an amince da ita ta FDA a matsayin magani na adjuvant don ciwon huhu mara ƙarami
Nov 2021: Hukumar Abinci da Magunguna ta amince da atezolizumab (Tecentriq, Genentech, Inc.) don maganin adjuvant a cikin marasa lafiya tare da mataki na II zuwa IIIA ciwon huhu mara ƙaranci (NSCLC) wanda ciwace-ciwacen su ya ƙunshi PD-L1 magana o..